$CALC News

CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate

Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

CalciMedica shares are trading higher. The company reported Q4 financial results.

CalciMedica shares are trading higher. The company reported Q4 financial results.

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Q4 EPS $(0.69) Misses $(0.42) Estimate

CalciMedica FY EPS $(1.97) Misses $(1.62) Estimate, Cash Balance Of $13M Provides Cash runway Into Q4 2026

How Is The Market Feeling About CalciMedica Inc?

CalciMedica shares are trading lower after HC Wainwright & Co. downgraded the stock from Buy to Neutral rating.

CalciMedica’s stock drops 75% on acute kidney injury trial termination

HC Wainwright & Co. Downgrades CalciMedica to Neutral

CalciMedica shares are trading lower after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Shares Halted On Circuit Breaker To The Upside, Stock Now Down -68.16%

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

CalciMedica Discontinued Its Phase 2 KOURAGE Trial Of Auxora For Stage 2 Or Stage 3 Acute Kidney Injury With Associated Acute Hypoxemic Respiratory Failure, Following A Recommendation From The Trial's Independent Data Monitoring Committee

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension